Bharat Biotech's intranasal vaccine gets regulator nod for Phase 2/3 trials

It is the first nasal vaccine in the country that has received the regulatory approval for late-stage clinical trials

The intranasal vaccine against coronavirus being developed by Bharat Biotech and supported by Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) has got the regulator nod for Phase 2-3 trials.

Bharat Biotech's intranasal vaccine is the first nasal vaccine in the country that has received the regulatory approval for Phase 2/3 trials, the Ministry of Science and Technology said in a statement.

"This is the first of its kind Covid-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis,